BNC105P Combination Study in Partially Platinum Sensitive Ovarian Cancer Patients

Mise à jour : Il y a 4 ans
Référence : NCT01624493

Femme Homme

Extrait

This phase I/II trial will determine the recommended dose and activity of BNC105P for patients with partially platinum sensitive ovarian cancer in first or second relapse.


Critère d'inclusion

  • Ovarian Cancer

Liens